MedTech SuperConnector (MTSC) is an open experiment in medtech acceleration from research bench to a physical device, technology, application or service to improve people's health and wellbeing.
At a glance
The MedTech SuperConnector (MTSC) is a £6 million accelerator programme funded by Research England via the Connecting Capability Fund (CCF). The RCA is part of a consortium led by Imperial with other partners including the Francis Crick Institute, ICR, Queen Mary University, RCM, RVC and Bucks New University.
“The accelerator programme is a journey, which involves a series of intensive training, masterclasses, market feasibility studies, coaching and mentoring, networking events and culminates in a public showcase, where each cohort of early career researchers present its results.”Head of Knowledge Exchange
MTSC brings together a cross-disciplinary capabilities in science, engineering, art and design. MTSC is an open experiment to link academic research, knowledge exchange, technology development, academic enterprise with industry, NHS and patients needs.
In its second year, the MTSC project aims to support early career researchers from the partner institutions to develop entrepreneurial skills and develop best practice around the translation of medtech discoveries into clinical practice and consumer use.
On 1 July 2020, the MTSC launched its final Cohort Four in partnership with GSK Consumer Healthcare Next/Beyond focusing on the Future of Pain challenge:
- Understanding – new and novel ways to understand and objectively measure pain
- Pre-emption and prevention – early interventions and preventative tools to reduce risk factors associated with pain
- Visualisation and interpretation – tools and approaches to support clinicians and individuals with the interpretation of data and alternative explanatory methods
- Management and treatment – new and novel ways to improve quality of life suffered by pain patients